Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
about
Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in MiceAdvances in phage display technology for drug discovery.Kallikreins - The melting pot of activity and functionA comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.Phage display-derived human antibodies in clinical development and therapyAn open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.2D-LC-MS/MS to measure cleaved high-molecular-weight kininogen in human plasma as a biomarker for C1-INH-HAE.Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.The Plasma Kallikrein-Kininogen Pathway Is Critical in the Pathogenesis of Colitis in Mice.Activity of Factor XII-Locarno.Selectivity Conversion of Protease Inhibitory AntibodiesComparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
P2860
Q27314976-8BC5DA55-0FF4-40F2-B25E-1BBE2C5A6F3EQ35614190-D1241311-C847-496D-AE36-2CC960AD50F4Q36563056-B2D6AEA9-B238-466C-9FFA-EA014CD8E021Q36767718-674E23F7-3CAE-4360-B2B1-7073736005D4Q37098934-F6F8E248-9A22-4DF7-A4C9-325D6DF951A8Q41416393-126E648A-B0EF-4DF2-8613-DF36B11C8BB4Q42371236-69C672B8-E40C-4BA7-A4FA-CEAFFF8ACDE9Q47180647-07B96736-5D88-4B74-8D11-82C5A5D2F415Q47796115-A5584F5E-5C0A-4B6A-8BF9-FD20D37A1EB3Q49954636-148CE6E1-68BC-400E-B76F-5E25BA2C22F6Q50034387-14445A86-1E44-410B-818C-2AE14EA8CC77Q50575704-574E1F26-1A5D-4023-8001-F5FAD4E0448AQ50961053-0141B410-5DD9-49B5-8329-EEF73EB149F4Q52691421-8CFBE0EE-8319-4B73-B2CC-CE427B6CF218Q52735481-5575F4BE-B90E-4A1F-8F51-FC6C75DEBF96Q58556656-89DF58E6-42D6-44E4-986E-A1F2120C455FQ58586459-893FD556-F817-4277-932B-21B0E86AD384
P2860
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@ast
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@en
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@nl
type
label
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@ast
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@en
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@nl
prefLabel
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@ast
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@en
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@nl
P2093
P2860
P3181
P356
P1476
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
@en
P2093
Allison P Lindberg
Andrew E Nixon
Burt A Adelman
Christopher TenHoor
Diana Martik
Gregory P Conley
Janja Cosic
Jon A Kenniston
Kris J Kopacz
P2860
P304
P3181
P356
10.1074/JBC.M114.569061
P407
P577
2014-08-22T00:00:00Z